Full-Time

Finance Manager

Contract Manufacturing

Updated on 8/1/2026

Deadline 10/5/26
Insulet Corporation

Insulet Corporation

5,001-10,000 employees

Develops tubeless insulin pumps and pods

Compensation Overview

$101.2k - $151.8k/yr

+ Incentive compensation

Acton, MA, USA

Hybrid

Hybrid work with required on-site work from an Insulet office.

Category
Finance & Banking (1)
Required Skills
Power BI
ERP
Data Visualization
Forecasting
SAP Products
Financial analysis
Tableau
Alteryx
Oracle
Excel/Numbers/Sheets
Financial Modeling

Get referred to Insulet Corporation

See people who can refer or advise you

Requirements
  • A bachelor's degree in Finance, Accounting, or a related field is required.
  • At least 8 years of experience in financial analysis, cost accounting, or operations finance is required, preferably in a manufacturing or contract manufacturing organization environment.
  • Strong understanding of manufacturing and supply chain processes and flows, related cost structures, inventory accounting, and supply chain finance is required.
  • Proficiency in enterprise resource planning systems such as SAP, Oracle, or similar systems, and advanced Excel skills are required.
  • The role requires analytical, communication, and business partnering skills.
  • The ability to manage multiple priorities and work cross-functionally in a fast-paced global environment is required.
Responsibilities
  • Lead monthly financial close activities for contract manufacturing, including inventory accruals, reconciliations, cost updates, and variance analysis.
  • Drive simplicity and efficiency into monthly activities and transactions to reduce the time and effort required to accurately close the general ledgers.
  • Prepare and present financial reports on contract manufacturing and site performance, including cost trends, inventory levels, and margin impacts.
  • Analyze actual versus forecasted results and provide insights to support operational and strategic decisions.
  • Develop and maintain dashboards and key performance indicators to monitor financial performance across third-party and internal manufacturing.
  • Support the development of the annual budget and quarterly forecasts related to operational variances, local spending where applicable, and inventory fluctuations.
  • Support Operational Quality departments with forecasting and variance analysis.
  • Track and analyze manufacturing costs, including material, labor, overhead, and logistics associated with third-party and Irvine operations.
  • Monitor inventory levels at contract manufacturing sites, the Irvine facility, and specific consigned inventories at vendor locations, ensuring accurate valuation, inventory controls, and reporting.
  • Partner with supply chain and operations teams to optimize inventory turns and reduce unplanned excess or obsolete stock.
  • Ensure compliance with internal controls and accounting standards related to inventory and cost of goods sold.
  • Support and maintain compliance with Sarbanes-Oxley requirements, including documentation and testing of key controls.
  • Collaborate with internal audit and external auditors to facilitate reviews and implement corrective actions as needed.
  • Provide guidance and support related to transactional flows within the Insulet enterprise resource planning system, including the design and recognition of earned overhead absorption.
  • Ensure compliance with and execution of contract manufacturing contract terms and business agreements within internal accounting processes.
  • Conduct compliance audits related to fixed assets located at remote contract manufacturing facilities.
  • Support contract negotiations with contract manufacturing organizations by providing financial modeling, cost benchmarking, and scenario analysis.
  • Collaborate with procurement, legal, and operations teams to evaluate commercial terms, supply chain strategies, and financial implications.
  • Serve as the finance lead for contract manufacturing and support the Irvine site regarding relationship management, ensuring alignment on performance metrics and cost expectations.
  • Identify and drive opportunities for cost savings and operational efficiency.
Desired Qualifications
  • Experience working with third-party manufacturers or outsourced production models.
  • Familiarity with contract review and implementation and financial risk assessment.
  • Knowledge of standard costing, variance analysis, and inventory reconciliation.
  • Experience with data visualization and analysis tools such as Power BI, Tableau, and Alteryx.
  • A Certified Public Accountant, Certified Management Accountant, or Master of Business Administration is preferred.

Insulet Corporation designs, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its flagship product, the Omnipod, is a tubeless, waterproof insulin pump that delivers a continuous subcutaneous infusion of insulin through disposable pods controlled by a personal diabetes manager. The system works by wearing a pod on the body, programming insulin delivery via the PDM (or a connected device), and, in newer versions like Omnipod 5, integrating with continuous glucose monitors to automatically adjust insulin delivery. Compared with many competitors, Insulet emphasizes a tubeless, wireless pump with a disposable pod ecosystem, adding automated insulin delivery features and CGM integration to streamline diabetes care. The company aims to simplify and improve diabetes management, offering a convenient and discreet insulin delivery method to reduce the burden of daily diabetes care for users around the world.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Get referred to Insulet Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Omnipod 5 launched in Spain in Q2 2026 as Insulet's 20th automated diabetes tech market globally.
  • Insulet hired first Chief R&D Officer Divakar Ramakrishnan in June 2026 to accelerate Omnipod 6 and pipeline development.
  • Omnipod 5 integrates with Abbott's FreeStyle Libre 3 Plus sensor, expanding user choice and real-time monitoring capabilities.

What critics are saying

  • Recurring cannula tear defects caused 24 serious adverse events including DKA, with $50M cost exposure and 70–90% recurrence risk in 3–6 months.
  • Two securities fraud class actions allege undisclosed manufacturing defects, with lead plaintiff deadline August 31, 2026 and 80–100% litigation success probability.
  • FDA may classify recall as 'most serious' type, risking full market suspension if corrective actions fail to prevent repeat cannula tears in 12–18 months.

What makes Insulet Corporation unique

  • Omnipod 5 is the only tubeless automated insulin delivery system approved for both type 1 and type 2 diabetes in the U.S.
  • Omnipod 5 now supports a 100 mg/dL glucose target with six customizable settings for tighter glycemic control.
  • Over 90% of insured U.S. patients are covered for Omnipod 5, enabling strong market penetration despite recalls.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Africa Business Watch
Jul 21st, 2026
Pomerantz law Firm announces the filing of a class action against Insulet Corporation and certain officers - PODD.

Pomerantz law Firm announces the filing of a class action against Insulet Corporation and certain officers - PODD. NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) - Pomerantz LLP announces that a class action lawsuit has been filed against Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 26-cv-13062, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Insulet securities between February 21, 2025 and May 26, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. If you are an investor who purchased or otherwise acquired Insulet securities during the Class Period, you have until August 31, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States ("U.S.") and internationally. The Company offers, inter alia, its "Omnipod 5" automated insulin delivery ("AID") system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and its "Omnipod Dash", which features a Bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager. Insulet also formerly offered the Omnipod Insulin Management System, its predecessor to the Omnipod 5, prior to the Class Period, but had already begun to phase out the product by the start of the Class Period. The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Insulet's manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times. The truth began to emerge on March 12, 2026, when Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod(R) 5 Pods after identifying a manufacturing issue through its ongoing product monitoring." On this news, Insulet's stock price fell $16.23 per share, or 6.88%, to close at $219.84 per share on March 13, 2026. Then, on May 26, 2026, Insulet disclosed the "initat[ion]" of another "voluntary Medical Device Correction", this time "for specific lots of Omnipod(R) 5, Omnipod Dash(R), and Omnipod(R) Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery." On this news, Insulet's stock price fell $7.79 per share, or 5.07%, to close at $146.01 per share on May 27, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

50states.com
Jul 18th, 2026
Lead plaintiff deadlines in shareholder class action lawsuits against Insulet Corporation (PODD), Photronics, Inc. (PLAB), and Planet Fitness, Inc. (PLNT) announced by Holzer & Holzer, LLC.

Lead plaintiff deadlines in shareholder class action lawsuits against Insulet Corporation (PODD), Photronics, Inc. (PLAB), and Planet Fitness, Inc. (PLNT) announced by Holzer & Holzer, LLC. ATLANTA, July 18, 2026 (GLOBE NEWSWIRE) - Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: Insulet Corporation (PODD) The shareholder class action lawsuit filed against Insulet Corporation ("Insulet") (NASDAQ: PODD) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between February 21, 2025 and May 26, 2026 regarding Insulet's manufacturing controls and procedures. If you purchased Insulet shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm's website at www.holzerlaw.com/case/insulet/ to learn more. The deadline to ask the court to be appointed lead plaintiff in the case is August 31, 2026. Photronics, Inc. (PLAB) The shareholder class action lawsuit filed against Photronics, Inc. ("Photronics") (NASDAQ: PLAB) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between December 10, 2025 and May 27, 2026 regarding Photronics' high-end product pipeline and the stability of the alleged demand for its products. If you purchased Photronics shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm's website at www.holzerlaw.com/case/photronics/ to learn more. The deadline to ask the court to be appointed lead plaintiff in the case is September 4, 2026. Planet Fitness, Inc. (PLNT) The shareholder class action lawsuit filed against Planet Fitness, Inc. ("Planet Fitness") (NYSE: PLNT) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between November 6, 2025 and May 6, 2026 regarding Planet Fitness' ability to nationally rollout its Black Card price increase, membership growth, and marketing strategy. If you purchased Planet Fitness shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm's website at www.holzerlaw.com/case/planet-fitness/ to learn more. The deadline to ask the court to be appointed lead plaintiff in the case is September 14, 2026. Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, https://holzerlaw.com/, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. 50 States Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

African SMB Journal
Jul 17th, 2026
PODD legal Deadline notice: important Insulet Deadline in Securities Fraud Class Action is approaching - investors notified to Contact BFA Law by August 31.

PODD legal Deadline notice: important Insulet Deadline in Securities Fraud Class Action is approaching - investors notified to Contact BFA Law by August 31. A securities fraud class action lawsuit has been filed on behalf of Insulet investors after its stock plummeted over 6% because of misrepresentation about the safety of Insulet's Omnipod products. NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ:PODD) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Insulet, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/insulet-class-action-lawsuit. Key Details of the Insulet ($PODD) Class Action: * Lead Plaintiff Deadline: August 31, 2026 * Alleged Misconduct: Securities fraud relating to the safety of Insulet's Omnipod products * Largest Alleged Stock Drop: March 12, 2026 - 6.88% Stock Drop * Court: U.S. District Court for the District of Massachusetts * Take Action: Contact BFA Law to discuss your rights Insulet investors have until August 31, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Insulet securities. The class action is pending in the U.S. District Court for the District of Massachusetts. It is captioned Hu v. Insulet Corporation et al., No. 26-cv-13062. Why is Insulet Being Sued for Securities Fraud? Insulet is primarily engaged in the development, manufacture, and sale of insulin delivery systems for people with insulin-dependent diabetes through its Omnipod platform. The Omnipod platform includes: the Omnipod(R) 5 Automated Insulin Delivery System ("Omnipod 5"), the Omnipod DASH(R) Insulin Management System ("Omnipod DASH"), and the Omnipod Insulin Management System ("Omnipod Eros"). Throughout the relevant period, Insulet misrepresented the safety of its Omnipod products as well as its ability to efficiently produce "medical grade quality at consumer electronic scale." In reality, certain of Insulet's products suffered from undisclosed manufacturing defects that put patient safety at risk. Why did Insulet's Stock Drop? On March 12, 2026, Insulet disclosed that a manufacturing issue with its Omnipod(R) 5 Pods caused a "tear in the internal tubing that delivers insulin" resulting in insulin being released inside the Pod "instead of being fully infused into the body as intended." Accordingly, Insulet "initiated a voluntary Medical Device Correction for specific lots of Omnipod(R) 5 Pods." This news caused the price of Insulet stock to drop $16.23 per share, or 6.88%, from a closing price of $236.07 per share on March 12, 2026, to $219.84 per share on March 13, 2026. On May 26, 2026, Insulet announced another voluntary Medical Device Correction due to a manufacturing issue, this time to its Omnipod 5, Omnipod DASH, and Omnipod Eros systems. It again indicated that the manufacturing issue resulted in a tear in the tubing which "could result in insulin under-delivery." This news caused the price of Insulet stock to drop $7.79 per share, or 5.07%, from a closing price of $218.11 per share on May 26, 2026, to $146.01 per share on May 27, 2026. What Can You Do? If you invested in Insulet, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. Attorney advertising. Past results do not guarantee future outcomes. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa SMB Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Yahoo Finance
Apr 9th, 2026
Analysts see 75% upside on Insulet despite 11% drop in 2026

Insulet Corporation has a consensus analyst price target of $360, implying 75% upside, with over 90% of analysts maintaining bullish ratings as of 6 April 2026. However, shares have fallen over 11% year-to-date and hit a 52-week low of $202.44 on 2 April, down more than 16% from a year earlier. The medical device company, which manufactures the Omnipod tubeless insulin pump, appointed Mike Panos as executive vice president and chief commercial officer on 30 March to strengthen commercial capabilities. CEO Ashley McEvoy cited significant growth opportunities driven by expanding global adoption of automated insulin delivery systems as the standard of care for both type 1 and type 2 diabetes.

Massachusetts Life Sciences Center
Apr 2nd, 2026
MLSC partners highlight innovation and access at MassMEDIC Symposium and Gala.

MLSC partners highlight innovation and access at MassMEDIC Symposium and Gala. * April 2, 2026 As a proud sponsor of the 2026 MassMEDIC Medtech Impact Symposium and Gala, the Massachusetts Life Sciences Center (MLSC) joined partners and awardees from across the life sciences community to showcase the collaborations and investments driving meaningful progress for patients on a global scale. The Symposium brought together ecosystem leaders to explore how the medtech industry can deliver better outcomes while managing costs and sustaining innovation. In the afternoon, the Symposium shifted to three dynamic, concurrent panel tracks that examined the evolving landscape of healthcare delivery. Each panel featured practical, forward-looking dialogue focused on users, enabling technologies, and the accelerating shift in where care is delivered. MLSC-supported companies and partners played a key role throughout these discussions. Insulet Corporation, a crucial partner of the MLSC's Pathmaker program and a recipient of multiple Tax Incentive awards, participated in the panel, Everything, Everywhere, All the Time, which examined how healthcare systems balance quality, cost, and access in an increasingly complex environment. Panelists discussed how economic pressures, information gaps, and misaligned incentives continue to influence decision-making across the healthcare system. The MLSC has awarded Insulet with $16.3 million in tax incentives for the creation of 834 jobs. To date, the MLSC has invested $13.5 million in Pathmaker training organizations across Massachusetts, supporting more than 1,200 training opportunities and connecting graduates with 101 companies across the life sciences sector. Later in the afternoon, Gentuity, an industry partner of the MLSC's Bits to Bytes program, joined the panel, Talking Tech: Interventional Systems, where industry leaders shared perspectives on emerging trends and product innovation in interventional medical technologies. Through the Bits to Bytes program, the MLSC supports companies developing data-driven solutions that are advancing diagnosis and treatment. Over the past seven years, the program has awarded $27.6 million in capital funding to non-profit universities and academic medical centers who have partnered with companies like Gentuity, helping them bring cutting-edge technologies closer to patients. Rounding out the Symposium, MLSC COO Elizabeth Graham moderated a panel on assistive and autonomous technologies in clinical workflows, joined by leadership members of Johnson & Johnson MedTech - a longtime sponsor of the MLSC's Massachusetts Next Generation (MassNextGen) Initiative - and Robeauté, a company pioneering a new class of therapeutic microrobots. The discussion explored how tools such as surgical robotics, fully automated technologies, and critical care technologies are transforming care delivery, and examined the growing intersection of human expertise and automation. Since its founding in 2018, the MLSC's MassNextGen portfolio has grown to 39 companies, including 19 previous awardees that have raised seed or Series A financing. To date, MassNextGen companies have raised more than $401 million in follow-on funding. Reflecting the program's strong support for medical innovation, 28 percent of MassNextGen companies are developing novel technologies in the medical device space with the goal of improving patients' lives around the world. The day concluded with the Medtech Impact Gala, where the themes of the Symposium were reflected through powerful stories from patients and innovators. The evening celebrated the real-world impact of medical technology and recognized the individuals and organizations working to improve care around the world. The MLSC was proud to sponsor this event alongside several industry leaders and Tax Incentive awardees, including Insulet Corporation, Optikos, TransMedics, and ZOLL. Applications for several MLSC programs are now open, including Pathmaker, and both Impact Catalyst and MassNextGen with a deadline of June 12, 2026, at 1 p.m. EST. Announcements